CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) Can’t Be More Risky. Short Interest Increased

January 14, 2018 - By Peter Erickson

Investors sentiment increased to 8 in Q3 2017. Its up 7.00, from 1 in 2017Q2. It is positive, as 2 investors sold Cannabis Science, Inc. shares while 0 reduced holdings. 0 funds opened positions while 1 raised stakes. 304,780 shares or 15.15% less from 359,180 shares in 2017Q2 were reported.
Neville Rodie Shaw Inc reported 95,000 shares. Oxbow Advsrs Limited Liability owns 15,000 shares for 0% of their portfolio. Frontier Investment Management owns 20,000 shares for 0% of their portfolio. Moreover, Rothschild Invest Corp Il has 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS). Toth Finance Advisory Corporation, a Virginia-based fund reported 11,000 shares. Stonebridge Advsr Ltd Company has 10,000 shares for 0% of their portfolio. North Star Asset Management stated it has 40,000 shares. Donaldson Mgmt Ltd Liability Corporation owns 99,780 shares.

The stock of CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) registered an increase of 4496.67% in short interest. CBIS’s total short interest was 689,500 shares in January as published by FINRA. Its up 4496.67% from 15,000 shares, reported previously.

The stock decreased 1.37% or $0.00137 during the last trading session, reaching $0.09863. About 29.72 million shares traded. Cannabis Science, Inc. (OTCMKTS:CBIS) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $251.69 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.

More notable recent Cannabis Science, Inc. (OTCMKTS:CBIS) news were published by: which released: “Cannabis Science Has US Federal Government Clearance that Changes the Industry …” on January 05, 2018, also with their article: “Cannabis Science Negotiates With Crown Baus Capital Corp (OTC: CBCA) for …” published on January 03, 2018, published: “Cannabis Science Actively Pursuing US Federal Government Contracts and Is …” on January 09, 2018. More interesting news about Cannabis Science, Inc. (OTCMKTS:CBIS) were released by: and their article: “Cannabis Science Announces its Construction Project Management (CPMT) Teams in …” published on January 10, 2018 as well as‘s news article titled: “Cannabis Science Acquires Second PRE ICO Dispensary” with publication date: December 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: